Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro (tirzepatide) typically begins to reduce appetite within the first one to two weeks of treatment, though meaningful weight changes on the scale usually appear from weeks four to eight. The medicine works by activating two gut-hormone receptors, GIP and GLP-1, which slow gastric emptying and signal fullness to the brain. Because Mounjaro is a prescription-only medicine, a clinician assesses your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest answer is: subtle. The 2.5mg starting dose exists to let your body adjust to tirzepatide, not to produce rapid weight loss. Nausea, a feeling of early fullness, or mild digestive changes are the most commonly noticed effects in this window, and they are, paradoxically, signs the medicine is doing something. Your stomach is emptying more slowly than before. Food that once felt like a normal portion may now feel like too much.
Some people also notice they are simply less preoccupied with food between meals. That shift in the background noise of hunger is one of the earliest signals that tirzepatide's dual-receptor action is working. It is not dramatic. A question our prescribers hear regularly is whether the first pen is faulty because nothing dramatic has happened. It isn't. The first four weeks are an adjustment, and the scale is rarely the right place to look yet.
Gastrointestinal effects (nausea, loose stools, burping, or constipation) tend to peak in the first days after each new dose and settle within a week or two for most people. If you are wondering how soon you feel the effects of Mounjaro and whether what you are experiencing is typical, keeping a pen in the fridge door and taking your injection on the same evening each week helps build a routine that makes side effects more predictable and easier to manage.
For most people, the scale starts to move meaningfully somewhere between weeks four and eight. That coincides with a dose increase to 5mg, where tirzepatide's therapeutic effect becomes more pronounced. The NHS patient information for tirzepatide confirms that weight loss builds progressively as treatment continues, rather than arriving all at once.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed thousands of adults over 72 weeks. At the 15mg maintenance dose, average body-weight reduction reached around 20–21%. That figure was not achieved at week one or even week eight, it accumulated across the full titration schedule as doses increased. Understanding when Mounjaro takes effect and why that gradient matters is important: slow early progress is normal, not failure.
If you are tracking weekly, expect variation. Water retention, hormonal cycles, and bowel habits all move the number independently of fat loss. Waist measurements and how clothes fit often reflect real change before the scales catch up. You can read more about how tirzepatide's effects develop over time for a fuller picture of what to expect at each phase.
Yes, substantially. This is one of the most practical things to understand about tirzepatide's mechanism. Each dose increase raises the level of receptor activation, which deepens the appetite-suppression effect and (over time) increases the rate of weight loss. The licensed titration schedule moves in 2.5mg steps, typically every four weeks, from the 2.5mg starter through to a maximum of 15mg.
People who reach higher doses generally report a more pronounced reduction in hunger and faster ongoing progress. But the titration is paced deliberately: moving too quickly increases the risk of GI side effects without proportionally improving outcomes. Your prescriber (not the pen count in your drawer) sets the pace. That pacing is part of why tirzepatide's clinical programme produced such consistent results across thousands of participants.
For context on how the cost of treatment fits into all of this, the Eli Lilly UK price changes from September 2025 are worth understanding before you commit to a titration plan. Treatment is a commitment across months, not a single pen.
Starting weight matters: people with higher starting BMIs often see larger absolute losses in the early weeks. Diet quality shapes the outcome too, tirzepatide reduces appetite but does not override consistently high-calorie choices. Protein adequacy is particularly important, because rapid weight loss without enough protein can erode muscle mass alongside fat. Staying well hydrated reduces the severity of GI effects and supports the process.
Alcohol, certain medicines, and underlying conditions can all influence the question of how soon Mounjaro works for any given person, which is precisely why a proper clinical assessment matters before treatment starts, rather than after. NICE guidance on tirzepatide (TA1026) addresses continuing treatment only where meaningful progress is achieved; if less than 5% weight loss has occurred by six months at the highest tolerated dose, the prescriber reviews whether to continue.
If you are already on treatment and unsure whether what you are noticing is normal, our frequently asked questions cover common concerns, and the aftercare team is available seven days a week. For anyone still deciding, speaking to our prescribers is the natural first step, same-day clinical review, no waiting list.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.